Medicus Pharma regains conditional Nasdaq equity compliance
Nasdaq notified Medicus Pharma on November 18, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders' equity for continued listing on the Nasdaq Capital Market. Nasdaq based its determination on approximately $4.25 million of completed equity financings and a $10.5 million debt exchange for non-convertible preferred shares. Compliance remains conditional on Medicus evidencing continued compliance in its next periodic report for the period ending Decem...
Key takeaways
Nasdaq confirmed that Medicus regained compliance with Listing Rule 5550(b)(1) in a notice received on November 18, 2026.
The continued-listing rule requires at least $2.5 million in shareholders' equity.
Medicus completed approximately $4.25 million of equity financings, consisting of a $3.0 million registered direct offering and approximately $1.25 million of private placements led by company insiders.
Dr. Raza Bokhari invested $750,000 through a controlled entity as part of the insider-led private placements.
The company exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares.
Continued compliance must be demonstrated in the next periodic report for the period ending December 31, 2026, or the company may be subject to delisting.
The company remains subject to Nasdaq's other continued-listing requirements.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MDCX in real time
Get material earnings, filing, IR, and earnings-call alerts by email.